<?xml version="1.0" encoding="UTF-8"?>
<p id="Par40">The production of egg-based influenza vaccines has remained virtually unchanged since the advent of split (subvirion) vaccines in the 1970s, and still commands 88% of the global market share in 2018 [
 <xref ref-type="bibr" rid="CR19">19</xref>]. The main advantages of the egg-based platform include an excellent production capacity that is capable of producing an estimated 1.5 billion doses annually, and a low production cost that allows global access to the vaccine [
 <xref ref-type="bibr" rid="CR20">20</xref>].
</p>
